Clinical trials: Botulinum toxin type A
Facial Rhytides, Crow's Feet Lines
Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines
This study will evaluate the safety and efficacy of botulinum toxin Type A compared to placebo for the treatment of Crow's Feet Lines and Frown Lines (Facial Rhytides)
- Conditions
- Facial Rhytides, Crow's Feet Lines, Glabellar Lines
- Trial name
- NCT01189760
- Testing
- onabotulinumtoxinA 24 U, onabotulinumtoxinA 44 U, normal saline
- Where
- 4 sites in United States, Canada and 2 more
- Volunteers
- 917 people
- Sponsor
- Allergan
N/A, as no Specific Medical Condition Will be Treated
A Study to Evaluate the Distribution of Botulinum Neurotoxin Type A Administered as Intradermal Injections, Comparing Different Doses, Concentrations, and Delivery Methods
The purpose of this study is to evaluate the distribution of IncobotulinumtoxinA (Xeomin) in healthy subjects at different volumes, concentrations and doses when administered intradermally and subcutaneously using different…
- Trial name
- NCT05585398
- Testing
- IncobotulinumtoxinA
- Where
- Germany
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Merz Pharmaceuticals GmbH
Glabellar Frown Lines
Study to Evaluate the Efficacy and Safety of MBA-P01 in Subjects With Glabellar Lines
This study is intended to evaluate the efficacy and safety of MBA-P01 compared to BOTOX in treatment of glabellar lines.
- Trial name
- NCT05059587
- Testing
- MBA-P01, BOTOX
- Where
- South Korea
- Volunteers
- 318 people
- Sponsor
- Medytox Korea
Lower Limb or Combined Lower Limb and Upper Limb Spasticity Due to Stroke or Traumatic Brain Injury
Study to Compare the Efficacy and Safety of NT 201 (Botulinum Toxin) With Placebo for the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury
The purpose of this study is to determine whether a single treatment with administration of 400 Units NT 201 (botulinum toxin) is superior to placebo (no medicine) for the treatment of lower limb spasticity caused by stroke or…
- Trial name
- PATTERN (NCT03992404)
- Testing
- NT 201
- Where
- 71 sites in United States, Belgium and 13 more
- Volunteers
- 603 people
- Sponsor
- Merz Pharmaceuticals GmbH
Crows Feet Lines
Efficacy and Safety of DWP450 for the Treatment of Crows Feet Lines
The purpose of this study is to evaluate the Efficacy and Safety of DWP450 treatment of Crows Feet Lines(CFL).
- Trial name
- NCT02882893
- Testing
- Clostridium Botulinum A Toxin
- Where
- South Korea
- Volunteers
- 238 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Spasmodic Torticollis
An Electrophysiological Study Of E2014 In Healthy Adult Male Japanese And Caucasian Subjects
To evaluate inter-ethnic similarity in pharmacodynamics between Japanese and Caucasian healthy adult male subjects by comparing electrophysiological reactions after administering E2014 to extensor digitorum brevis muscle (EDB).
- Trial name
- NCT00280384
- Testing
- E2014 (Botulinum toxin type B)
- Where
- Japan
- Volunteers
- 48 people
- Sponsor
- Eisai Limited
Glabellar Frown Lines
A Phase II Study to Evaluate the Efficacy and Safety of MBA-P01 in Subjects With Moderate to Severe Glabellar Lines
This study is intended to evaluate the efficacy and safety of MBA-P01 compared to placebo in treatment of glabellar lines.
- Trial name
- NCT05217355
- Testing
- MBA-P01 (Botulinum toxin A)
- Where
- South Korea
- Volunteers
- 50 people
- Sponsor
- Medytox Korea
Benign Masseteric Hypertrophy
Evaluate the Safety and Efficacy of Botulax® in Subjects With Benign Masseteric Hypertrophy
This study is A Randomized, Double-blind, Placebo-controlled, Multi-center Phase II Optimal Dose-finding Study to Evaluate the Safety and Efficacy of Botulax® in Subjects with Benign Masseteric Hypertrophy
- Trial name
- NCT04443244
- Testing
- Botulinum Toxin Type A Injection (Botulax®) 24Units, Botulinum Toxin Type A Injection (Botulax®) 48Units, Botulinum Toxin Type A Injection (Botulax®) 72Units
- Where
- South Korea
- Volunteers
- 80 people
- Sponsor
- Hugel
Spasticity, Stroke
A Randomized, Double Blind, Multi-center, Active Drug Controlled, Phase III Clinical Trial to Compare the Safety and Efficacy of DWP450 Versus Botox® in Treatment of Post Stroke Upper Limb Spasticity
Purpose: This study is a Randomized, Double Blind, Multi-center, Active Drug Controlled, Phase III Clinical Trial to Compare the Safety and Efficacy of DWP450 Versus Botox® in Treatment of Post Stroke Upper Limb(wrist, finger…
- Trial name
- NCT01945684
- Testing
- Botulinum toxin type A
- Where
- South Korea
- Volunteers
- 197 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Upper Limb Spasticity
A Study on Recombinant Botulinum Toxin Type A (YY001) for Injection in Multiple Treatments of Adult Upper Limb Spasticity
This is an open-label, multicenter, phase III clinical study to evaluate the long-term safety and efficacy of multiple treatments with recombinant botulinum toxin type A (YY001) for injection in adult upper limb spasticity
- Trial name
- NCT07478822
- Testing
- Recombinant botulinum toxin type A for injection (YY001)
- Where
- 16 sites in China
- Volunteers
- 300 people
- Sponsor
- Chongqing Claruvis Pharmaceutical Co., Ltd.
Glabellar Frown Lines
Study Comparing Treatment With Alluzience vs Reconstituted Toxin
This is a Phase IV, open-label, randomized, interventional, two-armed, multi-centre study to investigate subject treatment perception and Investigator treatment experience when using Alluzience or vacuum-dried botulinum…
- Trial name
- STAR (NCT05277337)
- Testing
- Alluzience, powder BoNT-A (BOTOX/Vistabel)
- Where
- 8 sites in Germany, United Kingdom
- Volunteers
- 150 people
- Sponsor
- Galderma R&D
Platysma Prominence
A Study of NT 201 Doses in the Treatment of Platysma Prominence
The purpose of this study is to assess the safety and efficacy of NT 201 in adults with moderate to severe platysma prominence.
- Trial name
- PAOLA (NCT05773053)
- Testing
- NT 201
- Where
- 7 sites in United States
- Volunteers
- 73 people
- Sponsor
- Merz Aesthetics GmbH
Glabellar Lines
Long-Term Patient Satisfaction of Facial Aesthetic Treatment With BOTOX®
This is an observational study assessing patient satisfaction following at least 5 years of BOTOX® treatment for glabellar lines.
- Trial name
- NCT01608672
- Testing
- botulinum toxin Type A
- Where
- 5 sites in United States, Australia and 3 more
- Volunteers
- 207 people
- Sponsor
- Allergan
Glabellar Lines
Clinical Trial to Evaluate the Safety and Efficacy of JTM201 to Treat Moderate or Severe Glabellar Lines
This is Multicenter, Randomized, Double-blind, Placebo-controlled, Single-dose Study to evaluate Safety and Efficacy of JTM201 in patients with Moderate or Severe Glabellar Lines
- Trial name
- NCT06246552
- Testing
- JTM201
- Where
- United States
- Volunteers
- 480 people
- Sponsor
- Jetema USA Inc.
Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)
Study of BOTOX Injections to Assess Change in Disease Activity and Adverse Events in Adult Female Participants With Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)
Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) is a chronic and debilitating urological complex of disorders characterized by symptoms of bladder pain or discomfort, mostly upon bladder filling, and often accompanied by…
- Trial name
- IC/BPS POC (NCT05141006)
- Testing
- BOTOX
- Where
- 43 sites in United States, Canada
- Volunteers
- 83 people
- Sponsor
- AbbVie
Masseter Muscle Prominence
A Study to Assess the Effectiveness of BOTOX (Botulinum Toxin Type A) Injections for the Change of Masseter Muscle Prominence in Adult Participants
The masseter muscle is one of the muscles in the lower face used for chewing. Prominence of the masseter muscle can appear as a widened and square lower face shape, which is an aesthetic concern for individuals who prefer a…
- Trial name
- MMP EU P3 (NCT06068855)
- Testing
- BOTOX
- Where
- 27 sites in Belgium, Bulgaria and 5 more
- Volunteers
- 249 people
- Sponsor
- AbbVie
Overactive Bladder
OnabotulinumtoxinA (BOTOX®) Treatment for Urinary Incontinence in Patients With Overactive Bladder
This is a study to evaluate the efficacy and safety of onabotulinumtoxinA (BOTOX®) compared with placebo, in achieving a 100% reduction in urinary incontinence in patients with overactive bladder (OAB) not properly managed with…
- Trial name
- COMFORT (NCT01945489)
- Testing
- onabotulinumtoxinA, Normal saline
- Where
- 40 sites in United States
- Volunteers
- 254 people
- Sponsor
- Allergan
Cervical Dystonia
Extension Study of ABP-19000 to Evaluate Safety and Efficacy of Repeat Treatments of ABP-450 in Cervical Dystonia
This Open-label Extension trial will evaluate the safety and efficacy of ABP-450 for the treatment of cervical dystonia in adults.
- Trial name
- NCT04871451
- Testing
- ABP-450
- Where
- 20 sites in United States
- Volunteers
- 51 people
- Sponsor
- AEON Biopharma, Inc.
Cervical Dystonia
Study to Assess the Efficacy and Safety of Dysport® in Cervical Dystonia
The aim is to demonstrate equivalent efficacy and safety in the treatment of the two most frequent forms of cervical dystonia (predominantly rotational torticollis and predominantly laterocollis) with the standard initial dose of…
- Trial name
- NCT00447772
- Testing
- Botulinum toxin type A
- Where
- 106 sites in Austria, Germany
- Volunteers
- 516 people
- Sponsor
- Ipsen
Migraine Disorders
A Study Using Botulinum Toxin Type A as Headache Prophylaxis for Migraine Patients With Frequent Headaches
This is a 60 week study including a double-blind phase followed by an open-label phase.
- Trial name
- NCT00168428
- Testing
- Botulinum Toxin Type A
- Where
- 6 sites in United States, Canada and 4 more
- Volunteers
- 705 people
- Sponsor
- Allergan